UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of May 2026 (Report No. 4)
Commission File Number: 001-40303
Inspira Technologies Oxy B.H.N. Ltd.
(Translation of registrant’s name into
English)
2 Ha-Tidhar St.
Ra’anana 4366504, Israel
(Address of principal executive office)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F:
☒ Form
20-F ☐ Form 40-F
CONTENTS
On May 18, 2026, Inspira Technologies Oxy B.H.N.
Ltd. (the “Company”) issued a press release titled “NYU Langone Issues $580,000 Purchase Order for Inspira's FDA-Cleared
ART100 Following Multi-Patient Hospital Evaluation,” a copy of which is furnished as Exhibit 99.1 with this Report of Foreign Private
Issuer on Form 6-K (this “Report”).
This Report is incorporated by
reference into the Company’s Registration Statements on Form F-3 (Registration Nos. 333-284308
and 333-289324) and Form S-8
(Registration Nos. 333-259057,
333-277980, 333-285565,
333-290162 and 333-292592),
filed with the Securities and Exchange Commission, to be a part thereof from the date on which this Report is submitted, to the extent
not superseded by documents or reports subsequently filed or furnished.
| Exhibit No. |
|
|
| 99.1 |
|
Press Release issued by Inspira Technologies Oxy B.H.N. Ltd. on May 18, 2026, titled “NYU Langone Issues $580,000 Purchase Order for Inspira's FDA-Cleared ART100 Following Multi-Patient Hospital Evaluation.” |
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
| |
Inspira Technologies Oxy B.H.N. Ltd. |
| |
|
|
| Date: May 18, 2026 |
By: |
/s/ Dagi Ben-Noon |
| |
|
Name: |
Dagi Ben-Noon |
| |
|
Title: |
Chief Executive Officer |
Exhibit
99.1
NYU
Langone Issues $580,000 Purchase Order for Inspira’s FDA-Cleared ART100 Following Multi-Patient Hospital Evaluation
RA’ANANA,
Israel, May 18, 2026 – Inspira Technologies Oxy B.H.N. Ltd. (Nasdaq: IINN, IINNW) (“Inspira” or the “Company”)
today announced that it has received a $580,000 commercial purchase order from NYU Langone Hospital in New York City (“NYU Langone”)
for the Company’s FDA-cleared ART100 extracorporeal blood circulation systems. The order was placed through Inspira’s U.S.
distributor following the successful completion of a multi-patient clinical evaluation at the hospital, and the systems are scheduled
for immediate fulfillment. This commercial milestone is in parallel with the Company’s previously disclosed active strategic process
involving the ART100 platform and broader medical assets.
The
purchase order follows the successful completion of an extensive hospital-based clinical evaluation, during which ART100 systems were
deployed in the treatment of more than 30 patients across a broad range of cardiopulmonary and surgical cases. The evaluation provided
NYU Langone with direct operational experience integrating the ART100 platform into the hospital workflows and led directly to the hospital’s
decision to transition from clinical assessment to commercial procurement.
“NYU
Langone’s transition from hospital-based evaluation to commercial purchase reflects the operational value of the ART100 platform
in real hospital use,” said Mike Hershkovitz, VP of Global Sales at Inspira Technologies. “This order provides an important
hospital reference as we continue commercial discussions with additional U.S. and international hospital systems evaluating extracorporeal
support technologies.”
“Our
search for the future of extracorporeal support through innovation and cost-effective technology led us to Inspira,” said Fred
Hill, Director of Extracorporeal Technology at NYU Langone Hospital. “The ART100 demonstrated the type of flexibility, usability,
and economic potential we believe will be important for the future of extracorporeal support.”
NYU
Langone is part of NYU Langone Health, a nationally recognized academic health system named to the 2025–2026 U.S. News & World
Report “Best Hospitals” Honor Roll and ranked No. 1 in the United States in multiple specialties, including cardiology, heart
and vascular surgery, pulmonology and lung surgery, neurology and neurosurgery, and geriatrics.
The
ART100 is a U.S. FDA-cleared extracorporeal blood circulation system intended for use in cardiopulmonary bypass procedures. The system
is currently active and under evaluation at additional U.S. hospitals. As previously disclosed, Inspira is advancing an active strategic
process involving multiple counterparties regarding potential transactions involving the ART100 system and additional medical assets.
The Company believes the purchase order from NYU Langone provides an important commercial reference point within this process.
About
Inspira Technologies
Inspira
Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) is a technology company focused on advanced connectivity and electronics manufacturing
solutions for next-generation hardware markets. Following its acquisition of the Additively Manufactured Electronics (AME) platform,
the Company is developing high-density, thermally optimized quantum connectivity solutions for dilution cryostats and advancing AME applications
for defense, aerospace, missile, space, and other mission-critical environments. Inspira also continues to advance its medical technology
portfolio, including respiratory support and blood monitoring platforms, while actively working to monetize certain parts of the medical
business. For more information, please visit: www.q-trex.com and www.inspira-technologies.com
Forward-Looking
Statement Disclaimer
This press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. These forward-looking
statements are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties
that could cause actual results to differ materially from those described in the forward-looking statements. For example, the Company
is using forward-looking statements when it discusses the benefits, advantages and capabilities of its ART100 system, that it is also
engaged in discussions with multiple counterparties regarding potential strategic transactions involving the ART100 system and additional
medical assets and its belief that the purchase order from NYU Langone provides an important commercial reference point within this process.
These forward-looking statements and their implications are based solely on the current expectations of the Company’s management
and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in
the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions
to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated
events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk
Factors” in the Company’s annual report on Form 20-F for the fiscal year ended December 31, 2025, filed with the U.S. Securities
and Exchange Commission (the “SEC”), which is available on the SEC’s website at www.sec.gov.
Company
Contact
Inspira Technologies
Email: info@inspirao2.com
Phone: +972-9-9664485
Investor
Relations Contact
Arx Investor Relations
North American Equities Desk
inspira@arxhq.com
